

Jee-Fu Huang

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3713557/jee-fu-huang-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

317
papers

6,344
citations

42
h-index

66
g-index

348
ext. papers

7,352
ext. citations

5.3
avg, IF

5.23
L-index

#	Paper	IF	Citations
317	Clinical characteristics and treatment outcomes of SARS-CoV-2 delta variant outbreak, Pingtung, Taiwan, June 2021.. <i>Journal of the Formosan Medical Association</i> , 2022 ,	3.2	1
316	Outreach onsite treatment with a simplified pangenotypic direct-acting anti-viral regimen for hepatitis C virus micro-elimination in a prison.. <i>World Journal of Gastroenterology</i> , 2022 , 28, 263-274	5.6	0
315	Limited sorafenib anticancer effects on primary cultured hepatocellular carcinoma cells with high NANOG expression.. <i>Kaohsiung Journal of Medical Sciences</i> , 2022 , 38, 157-164	2.4	0
314	Dynamics of cytokines predicts risk of hepatocellular carcinoma among chronic hepatitis C patients after viral eradication.. <i>World Journal of Gastroenterology</i> , 2022 , 28, 140-153	5.6	0
313	Itemization difference of patient-reported outcome in patients with chronic liver disease.. <i>PLoS ONE</i> , 2022 , 17, e0264348	3.7	0
312	Persistent cryoglobulinemia after antiviral treatment is associated with advanced fibrosis in chronic hepatitis C patients.. <i>PLoS ONE</i> , 2022 , 17, e0268180	3.7	0
311	Establishment of an outreach, grouping healthcare system to achieve microelimination of HCV for uremic patients in haemodialysis centres (ERASE-C). <i>Gut</i> , 2021 , 70, 2349-2358	19.2	7
310	Towards a safe hospital: hepatitis C in-hospital micro-elimination program (HCV-HELP study). <i>Hepatology International</i> , 2021 , 1	8.8	2
309	Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha-fetoprotein levels. <i>Cancer Medicine</i> , 2021 ,	4.8	2
308	The Impact of Steatosis on Chronic Hepatitis C Progression and Response to Antiviral Treatments. <i>Biomedicines</i> , 2021 , 9,	4.8	2
307	Association Between Fatty Liver and Cirrhosis, Hepatocellular Carcinoma, and Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2021 , 224, 294-302	7	10
306	Genotype distribution, clinical characteristics, and racial differences observed in chronic hepatitis C patients in Pingtung, Taiwan. <i>Journal of the Chinese Medical Association</i> , 2021 , 84, 255-260	2.8	1
305	Potential of novel colchicine dosage schedule for the palliative treatment of advanced hepatocellular carcinoma. <i>Kaohsiung Journal of Medical Sciences</i> , 2021 , 37, 616-623	2.4	0
304	Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan. <i>Liver International</i> , 2021 , 41, 1265-1277	7.9	7
303	Long-term risk of end-stage renal diseases with maintenance dialysis among chronic hepatitis C patients after antiviral therapy in Taiwan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021 , 36, 2247-2254	4	1
302	Significant amelioration of hepatitis C virus infection in a hyperendemic area: longitudinal evidence from the COMPACT Study in Taiwan. <i>BMJ Open</i> , 2021 , 11, e042861	3	3
301	Comorbidities in patients with chronic hepatitis C and hepatitis B on hemodialysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021 , 36, 2261-2269	4	1

300	Significant down-regulation of growth hormone receptor expression revealed as a new unfavorable prognostic factor in hepatitis C virus-related hepatocellular carcinoma. <i>Clinical and Molecular Hepatology</i> , 2021 , 27, 313-328	6.9	2
299	Changing epidemiology and viral interplay of hepatitis B, C and D among injecting drug user-dominant prisoners in Taiwan. <i>Scientific Reports</i> , 2021 , 11, 8554	4.9	5
298	Role of hepatitis D virus infection in development of hepatocellular carcinoma among chronic hepatitis B patients treated with nucleotide/nucleoside analogues. <i>Scientific Reports</i> , 2021 , 11, 8184	4.9	3
297	Resubclassification and clinical management for Barcelona Clinic Liver Cancer Stage C hepatocellular carcinoma. <i>Hepatology International</i> , 2021 , 15, 946-956	8.8	2
296	Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort). <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021 , 36, 2884-2892	4	0
295	The association between hepatitis C virus infection and renal function. <i>Journal of the Chinese Medical Association</i> , 2021 , 84, 757-765	2.8	1
294	Genetic polymorphisms of regulatory T cell-related genes modulate systemic inflammation induced by viral hepatitis. <i>Kaohsiung Journal of Medical Sciences</i> , 2021 , 37, 1000-1009	2.4	0
293	Eradication of hepatitis C virus preserve liver function and prolong survival in advanced hepatocellular carcinoma patients with limited life expectancy. <i>Kaohsiung Journal of Medical Sciences</i> , 2021 , 37, 145-153	2.4	2
292	The case for simplifying and using absolute targets for viral hepatitis elimination goals. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 12-19	3.4	12
291	Effects of Cirrhosis and Diagnosis Scenario in Metabolic-Associated Fatty Liver Disease-Related Hepatocellular Carcinoma. <i>Hepatology Communications</i> , 2021 , 5, 122-132	6	3
290	Hepatitis b infection: progress in identifying patients most likely to respond to peginterferon alfa. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021 , 15, 427-435	4.2	6
289	Role of hepatitis D virus in persistent alanine aminotransferase abnormality among chronic hepatitis B patients treated with nucleotide/nucleoside analogues. <i>Journal of the Formosan Medical Association</i> , 2021 , 120, 303-310	3.2	1
288	Exosome-derived differentiation antagonizing non-protein coding RNA with risk of hepatitis C virus-related hepatocellular carcinoma recurrence. <i>Liver International</i> , 2021 , 41, 956-968	7.9	7
287	Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment. <i>Kaohsiung Journal of Medical Sciences</i> , 2021 , 37, 334-345	2.4	3
286	Coagulation-related inflammatory pseudotumor of liver. <i>Kaohsiung Journal of Medical Sciences</i> , 2021 , 37, 528-530	2.4	
285	Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis. <i>Clinical and Molecular Hepatology</i> , 2021 , 27, 186-196	6.9	2
284	The performance of HCV GT plus RUO reagent in determining Hepatitis C virus genotypes in Taiwan. <i>PLoS ONE</i> , 2021 , 16, e0246376	3.7	0
283	Concordance of SVR12, SVR24 and SVR durability in Taiwanese chronic hepatitis C patients with direct-acting antivirals. <i>PLoS ONE</i> , 2021 , 16, e0245479	3.7	4

282	Evolutionary seroepidemiology of viral hepatitis and the gap in hepatitis C care cascades among uraemic patients receiving haemodialysis in Taiwan-the Formosa-Like Group. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 719-727	3.4	1
281	Anti-HCV antibody titer highly predicts HCV viremia in patients with hepatitis B virus dual-infection. <i>PLoS ONE</i> , 2021 , 16, e0254028	3.7	0
280	Seroreversion of hepatitis B surface antigen among subjects with resolved hepatitis B virus infection: A community-based cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021 , 36, 3239-3246	4	
279	First-in-Asian double-blind randomized trial to assess the efficacy and safety of insulin sensitizer in nonalcoholic steatohepatitis patients. <i>Hepatology International</i> , 2021 , 15, 1136-1147	8.8	4
278	Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH). <i>Hepatology International</i> , 2021 , 15, 1109-1121	8.8	0
277	Scaling up the in-hospital hepatitis C virus care cascade in Taiwan. <i>Clinical and Molecular Hepatology</i> , 2021 , 27, 136-143	6.9	5
276	Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan.. <i>Infectious Diseases and Therapy</i> , 2021 , 11, 485	6.2	0
275	Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan. <i>Scientific Reports</i> , 2021 , 11, 23473	4.9	1
274	HCC risk post-SVR with DAAs in East Asians: findings from the REAL-C cohort. <i>Hepatology International</i> , 2020 , 14, 1023-1033	8.8	10
273	Severe acute exacerbation of HCV infection in cancer patients who undergo chemotherapy: Some issues. <i>Journal of Viral Hepatitis</i> , 2020 , 27, 1508	3.4	
272	Review of the present features and the infection control challenges of COVID-19 pandemic in dialysis facilities. <i>Kaohsiung Journal of Medical Sciences</i> , 2020 , 36, 393-398	2.4	4
271	Modelling NAFLD disease burden in four Asian regions-2019-2030. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 801-811	6.1	31
270	Primary culture of aspiration residual specimens improves the diagnostic accuracy between hepatocellular carcinoma and benign nodules. <i>Kaohsiung Journal of Medical Sciences</i> , 2020 , 36, 460-466	2.4	1
269	Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV/HCV co-infection. <i>Journal of Hepatology</i> , 2020 , 73, 62-71	13.4	36
268	Letter to the Editor: Regional Epidemics of Nonalcoholic Fatty Liver Disease: Timing of Westernization and Ethnicity Matter. <i>Hepatology</i> , 2020 , 72, 781	11.2	2
267	Primary cultures of aspiration residual specimens predict outcomes of hepatocellular carcinoma patients receiving curative treatment. <i>Kaohsiung Journal of Medical Sciences</i> , 2020 , 36, 750-756	2.4	1
266	Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritis. <i>Scientific Reports</i> , 2020 , 10, 5372	4.9	2
265	Serial serologic changes of hepatitis D virus in chronic hepatitis B patients receiving nucleos(t)ides analogues therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020 , 35, 1886-1892	4	4

264	The applicability of non-invasive methods for assessing liver fibrosis in hemodialysis patients with chronic hepatitis C. <i>PLoS ONE</i> , 2020 , 15, e0242601	3.7	2
263	DAA Therapy in Hepatitis C in Patients With Chronic Kidney Disease: New Information for GFR Category G4 and G5. <i>Clinical Gastroenterology and Hepatology</i> , 2020 ,	6.9	
262	Liquid Biopsy for the Diagnosis of Viral Hepatitis, Fatty Liver Steatosis, and Alcoholic Liver Diseases. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	10
261	Proteomic screening of saturated fatty acid-induced hepatocytes-derived exosomes.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e13568-e13568	2.2	
260	Circulating exosome DANCR correlated to the recurrence of hepatitis C virus-related hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e13688-e13688	2.2	
259	Less liver fibrosis marker increment in overweight chronic hepatitis B patients observed by age-adjusted Fibrosis-4 Index. <i>BMJ Open Gastroenterology</i> , 2020 , 7,	3.9	1
258	Early Fibrosis but Late Tumor Stage and Worse Outcomes in Hepatocellular Carcinoma Patients Without Hepatitis B or Hepatitis C. <i>Digestive Diseases and Sciences</i> , 2020 , 65, 2120-2129	4	7
257	Hepatitis C Virus Cure Rates Are Reduced in Patients With Active but Not Inactive Hepatocellular Carcinoma: A Practice Implication. <i>Clinical Infectious Diseases</i> , 2020 , 71, 2840-2848	11.6	14
256	Letter to the editor: Successful eradication of HCV by short-course DAAs in HCV-Positive donor to HCV-Negative recipient during Haplo-HSCT. <i>Journal of the Formosan Medical Association</i> , 2020 , 119, 1717-1718	2.2	2
255	Clusters of Circulating let-7 Family Tumor Suppressors Are Associated with Clinical Characteristics of Chronic Hepatitis C. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	2
254	Cure or curd: Modification of lipid profiles and cardio-cerebrovascular events after hepatitis C virus eradication. <i>Kaohsiung Journal of Medical Sciences</i> , 2020 , 36, 920-928	2.4	8
253	Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH). <i>American Journal of Gastroenterology</i> , 2020 , 115, 1226-1235	0.7	8
252	Viral Interference Between Dengue Virus and Hepatitis C Virus Infections. <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofaa272	1	2
251	Successful Antiviral Therapy Reduces Risk of Schizophrenia Among Chronic Hepatitis C Patients: A Nationwide Real-World Taiwanese Cohort (T-COACH). <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofaa397	1	0
250	Risk stratification of non-alcoholic fatty liver disease across body mass index in a community basis. <i>Journal of the Formosan Medical Association</i> , 2020 , 119, 89-96	3.2	10
249	Ribavirin facilitates early viral kinetics in chronic hepatitis C patients receiving daclatasvir/asunaprevir. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020 , 35, 151-156	4	5
248	Improvement of hyperuricemia in chronic hepatitis C patients receiving directly acting antiviral agents. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020 , 35, 473-481	4	4
247	Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium. <i>Hepatology International</i> , 2019 , 13, 587-598	8.8	22

246	Equal treatment efficacy of direct-acting antivirals in patients with chronic hepatitis C and hepatocellular carcinoma? A prospective cohort study. <i>BMJ Open</i> , 2019 , 9, e026703	3	15
245	Integrated care for methadone maintenance patients with hepatitis C virus infection. <i>Kaohsiung Journal of Medical Sciences</i> , 2019 , 35, 501-507	2.4	2
244	Axl and autophagy LC3 expression in tumors is strongly associated with clinical prognosis of hepatocellular carcinoma patients after curative resection. <i>Cancer Medicine</i> , 2019 , 8, 3453-3463	4.8	10
243	Mac-2 Binding Protein Glycosylation Isomer as a Hepatocellular Carcinoma Marker in Patients With Chronic Hepatitis B or C Infection. <i>Hepatology Communications</i> , 2019 , 3, 493-503	6	16
242	An Open-Label, Randomized, Active-Controlled Trial of 8 Versus 12 Weeks of Elbasvir/Grazoprevir for Treatment-Naive Patients With Chronic Hepatitis C Genotype 1b Infection and Mild Fibrosis (EGALITE Study): Impact of Baseline Viral Loads and NS5A Resistance-Associated Substitutions. <i>Journal of Infectious Diseases</i> , 2019 , 220, 557-566	7	10
241	Association of serial serum major histocompatibility complex class I chain-related A measurements with hepatocellular carcinoma in chronic hepatitis C patients after viral eradication. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019 , 34, 249-255	4	7
240	Wisteria floribunda agglutinin-positive Mac-2-binding protein in the prediction of disease severity in chronic hepatitis B patients. <i>PLoS ONE</i> , 2019 , 14, e0220663	3.7	12
239	The acceptability of serum sample storage for hepatitis C viral load analysis in chronic hepatitis C patients. <i>Advances in Digestive Medicine</i> , 2019 , 6, 58-61	0.1	
238	The prognostic factors between different viral etiologies among advanced hepatocellular carcinoma patients receiving sorafenib treatment. <i>Kaohsiung Journal of Medical Sciences</i> , 2019 , 35, 624-632	2.4	6
237	Pharmacokinetics and pharmacodynamics of pegylated interferon for the treatment of hepatitis B. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019 , 15, 779-785	5.5	11
236	Circulating exosomes of long non-coding RNA DANCR correlated to prognosis of Hepatitis C virus-related hepatocellular carcinoma. <i>FASEB Journal</i> , 2019 , 33, 662.69	0.9	
235	Elevated interleukin-4 levels predicted advanced fibrosis in chronic hepatitis C. <i>Journal of the Chinese Medical Association</i> , 2019 , 82, 277-281	2.8	2
234	Disease progression of nonalcoholic steatohepatitis in Taiwanese patients: a longitudinal study of paired liver biopsies. <i>European Journal of Gastroenterology and Hepatology</i> , 2019 , 31, 224-229	2.2	2
233	Elevated serum ferritin level associated with hepatic steatosis and fibrosis in hepatitis C virus-infected patients. <i>Journal of the Chinese Medical Association</i> , 2019 , 82, 99-104	2.8	3
232	Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions. <i>Journal of the Formosan Medical Association</i> , 2019 , 118, 556-564	3.2	8
231	Pretreatment Hepatitis B Viral Load Predicts Long-Term Hepatitis B Response After Anti-Hepatitis C Therapy in Hepatitis B/C Dual-Infected Patients. <i>Journal of Infectious Diseases</i> , 2019 , 219, 1224-1233	7	8
230	Fulminant Emphysematous Pancreatic Pseudocyst: Infected with Normal Skin Flora. <i>American Journal of Medicine</i> , 2019 , 132, e41-e42	2.4	
229	Role of IL-28B genetic variants in HCV-related liver disease severity in patients with different viral genotypes. <i>Medicine (United States)</i> , 2018 , 97, e9782	1.8	2

228	The treatment outcome and impact on blood transfusion demand of Peg-interferon/ribavirin in thalassemic patients with chronic hepatitis C. <i>Journal of the Formosan Medical Association</i> , 2018 , 117, 14-23	3.2	5
227	Identification of treatment-experienced hepatitis C patients with poor cost-effectiveness of pegylated interferon plus ribavirin from a real-world cohort. <i>Journal of the Formosan Medical Association</i> , 2018 , 117, 54-62	3.2	2
226	Boceprevir-based triple therapy to rescue HCV genotype 1/HBV dually infected patients refractory to peginterferon plus ribavirin combination therapy in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2018 , 117, 497-504	3.2	3
225	Paritaprevir/ritonavir/ombitasvir plus dasabuvir with ribavirin for treatment of recurrent chronic hepatitis C genotype 1 infection after liver transplantation: Real-world experience. <i>Journal of the Formosan Medical Association</i> , 2018 , 117, 518-526	3.2	11
224	Interference of hepatitis B virus dual infection in platelet count recovery in chronic hepatitis C patients with curative antiviral therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018 , 33, 1108-1114	4	4
223	More advanced disease and worse survival in cryptogenic compared to viral hepatocellular carcinoma. <i>Liver International</i> , 2018 , 38, 895-902	7.9	19
222	Poor adherence to hepatocellular carcinoma surveillance: A systematic review and meta-analysis of a complex issue. <i>Liver International</i> , 2018 , 38, 503-514	7.9	36
221	Association between cryoglobulinemia and liver fibrosis in chronic hepatitis C patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018 , 33, 1897-1903	4	6
220	A real world cost effectiveness analysis of interferon-based therapy for HCV in the super-responders. <i>Journal of the Chinese Medical Association</i> , 2018 , 81, 670-675	2.8	2
219	The IL-6/STAT3 pathway upregulates microRNA-125b expression in hepatitis C virus infection. <i>Oncotarget</i> , 2018 , 9, 11291-11302	3.3	11
218	Post-treatment alpha fetoprotein and platelets predict hepatocellular carcinoma development in dual-infected hepatitis B and C patients after eradication of hepatitis C. <i>Oncotarget</i> , 2018 , 9, 12240-12249	2.3	4
217	Impact of tumor size on the prognosis of hepatocellular carcinoma in patients who underwent liver resection. <i>Journal of the Chinese Medical Association</i> , 2018 , 81, 155-163	2.8	22
216	Post-treatment fibrotic modifications overwhelm pretreatment liver fibrosis in predicting HCC in CHC patients with curative antivirals. <i>Hepatology International</i> , 2018 , 12, 544-551	8.8	7
215	Association of hyperuricemia with disease severity in chronic hepatitis C patients. <i>PLoS ONE</i> , 2018 , 13, e0207043	3.7	7
214	Updates in the management and treatment of HCV genotype 3, what are the remaining challenges?. <i>Expert Review of Anti-Infective Therapy</i> , 2018 , 16, 907-912	5.5	8
213	The effect of antiviral therapy on serum lipid profiles in chronic hepatitis C. <i>Oncotarget</i> , 2018 , 9, 21313-21321	3.1	9
212	Lower protein expression levels of MHC class I chain-related gene A in hepatocellular carcinoma are at high risk of recurrence after surgical resection. <i>Scientific Reports</i> , 2018 , 8, 15821	4.9	2
211	Tolloid-like 1 genetic variants determine fibrosis regression in chronic hepatitis C patients with curative antivirals. <i>Scientific Reports</i> , 2018 , 8, 15058	4.9	4

210	Significant predictors of overall survival in patients with hepatocellular carcinoma after surgical resection. <i>PLoS ONE</i> , 2018 , 13, e0202650	3.7	11
209	Anti-viral therapy is associated with improved survival but is underutilised in patients with hepatitis B virus-related hepatocellular carcinoma: real-world east and west experience. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 44-54	6.1	17
208	Autophagy-related gene LC3 expression in tumor and liver microenvironments significantly predicts recurrence of hepatocellular carcinoma after surgical resection. <i>Clinical and Translational Gastroenterology</i> , 2018 , 9, 166	4.2	10
207	A real-world impact of cost-effectiveness of pegylated interferon/ribavirin regimens on treatment-naïve chronic hepatitis C patients in Taiwan. <i>Kaohsiung Journal of Medical Sciences</i> , 2017 , 33, 44-49	2.4	10
206	Derivation and validation of a scoring system for predicting nonalcoholic steatohepatitis in Taiwanese patients with severe obesity. <i>Surgery for Obesity and Related Diseases</i> , 2017 , 13, 686-692	3	10
205	Genetics Variants and Serum Levels of MHC Class I Chain-related A in Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis C Patients Post Antiviral Treatment. <i>EBioMedicine</i> , 2017 , 15, 81-89	8.8	25
204	25-Hydroxy vitamin D suppresses hepatitis C virus replication and contributes to rapid virological response of treatment efficacy. <i>Hepatology Research</i> , 2017 , 47, 1383-1389	5.1	13
203	Reactivation of hepatitis B in patients of chronic hepatitis C with hepatitis B virus infection treated with direct acting antivirals. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017 , 32, 1754-1762 ⁴		5 ¹
202	Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients. <i>Scientific Reports</i> , 2017 , 7, 3718	4.9	13
201	Pegylated interferon plus ribavirin combination therapy in postliver transplant recipients with recurrent hepatitis C virus infection. <i>Kaohsiung Journal of Medical Sciences</i> , 2017 , 33, 284-289	2.4	2
200	Identification of groups with poor cost-effectiveness of peginterferon plus ribavirin for naïve hepatitis C patients with a real-world cohort and database. <i>Medicine (United States)</i> , 2017 , 96, e6984	1.8	3
199	Cytokeratin-18 and uric acid predicts disease severity in Taiwanese nonalcoholic steatohepatitis patients. <i>PLoS ONE</i> , 2017 , 12, e0174394	3.7	10
198	Seroprevalence and clinical characteristics of viral hepatitis in transfusion-dependent thalassemia and hemophilia patients. <i>PLoS ONE</i> , 2017 , 12, e0178883	3.7	14
197	The impact of an additional extra-hepatic primary malignancy on the outcomes of patients with hepatocellular carcinoma. <i>PLoS ONE</i> , 2017 , 12, e0184878	3.7	3
196	The outcomes of glucose abnormalities in chronic hepatitis C patients receiving interferon-free direct antiviral agents. <i>Kaohsiung Journal of Medical Sciences</i> , 2017 , 33, 567-571	2.4	14
195	Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein expression predicts disease severity in chronic hepatitis C patients. <i>Kaohsiung Journal of Medical Sciences</i> , 2017 , 33, 394-399	2.4	7
194	Interactive effects between Lymphotoxin β 252 polymorphism and habits of substance use on risk of hepatocellular carcinoma. <i>Kaohsiung Journal of Medical Sciences</i> , 2017 , 33, 334-338	2.4	2
193	Independent and additive interaction between polymorphisms of tumor necrosis factor β 08 and lymphotoxin β 252 on risk of hepatocellular carcinoma related to hepatitis B. <i>Kaohsiung Journal of Medical Sciences</i> , 2017 , 33, 453-457	2.4	3

192	Time-Degenerative Factors and the Risk of Hepatocellular Carcinoma after Antiviral Therapy among Hepatitis C Virus Patients: A Model for Prioritization of Treatment. <i>Clinical Cancer Research</i> , 2017 , 23, 1690-1697	12.9	27
191	Disease severity and erythropoiesis in chronic hepatitis C. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017 , 32, 864-869	4	3
190	The Paradoxical Effects of Different Hepatitis C Viral Loads on Host DNA Damage and Repair Abilities. <i>PLoS ONE</i> , 2017 , 12, e0164281	3.7	6
189	Regional differences in treatment rates for patients with chronic hepatitis C infection: Systematic review and meta-analysis. <i>PLoS ONE</i> , 2017 , 12, e0183851	3.7	16
188	Risk of hepatitis C virus related hepatocellular carcinoma between subjects with spontaneous and treatment-induced viral clearance. <i>Oncotarget</i> , 2017 , 8, 43925-43933	3.3	9
187	Diversity of the association of serum levels and genetic variants of MHC class I polypeptide-related chain A with liver fibrosis in chronic hepatitis C. <i>Oncotarget</i> , 2017 , 8, 32618-32625	3.3	6
186	The autophagy marker LC3 strongly predicts immediate mortality after surgical resection for hepatocellular carcinoma. <i>Oncotarget</i> , 2017 , 8, 91902-91913	3.3	10
185	Lamivudine switch therapy in chronic hepatitis B patients achieving undetectable hepatitis B virus DNA after 3 years of entecavir therapy: A prospective, open-label, multicenter study. <i>Kaohsiung Journal of Medical Sciences</i> , 2016 , 32, 559-566	2.4	1
184	Pretreatment glucose status determines HCC development in HCV patients with mild liver disease after curative antiviral therapy. <i>Medicine (United States)</i> , 2016 , 95, e4157	1.8	22
183	MicroRNA let-7g cooperates with interferon/ribavirin to repress hepatitis C virus replication. <i>Journal of Molecular Medicine</i> , 2016 , 94, 311-20	5.5	7
182	Dynamics of PBMC gene expression in hepatitis C virus genotype 1-infected patients during combined peginterferon/ribavirin therapy. <i>Oncotarget</i> , 2016 , 7, 61325-61335	3.3	6
181	Interactions of a PPARGC1A Variant and a PNPLA3 Variant Affect Nonalcoholic Steatohepatitis in Severely Obese Taiwanese Patients. <i>Medicine (United States)</i> , 2016 , 95, e3120	1.8	19
180	Long-term efficacy of Peg-Interferon/Ribavirin with and without Lamivudine therapy for HBeAg-positive hepatitis B and C dual infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016 , 31, 835-41	4	6
179	Elevated on-treatment levels of serum IFN-gamma is associated with treatment failure of peginterferon plus ribavirin therapy for chronic hepatitis C. <i>Scientific Reports</i> , 2016 , 6, 22995	4.9	3
178	Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition. <i>Cancer Cell</i> , 2016 , 30, 879-890	24.3	119
177	APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. <i>Hepatology International</i> , 2016 , 10, 681-701	8.8	60
176	Anti-HIV seropositivity was related to HBsAg seropositivity among injecting drug users in Taiwan. <i>Kaohsiung Journal of Medical Sciences</i> , 2016 , 32, 96-102	2.4	3
175	Hepatitis D virus infections among injecting drug users with and without human immunodeficiency virus infection in Taiwan. <i>Kaohsiung Journal of Medical Sciences</i> , 2016 , 32, 526-530	2.4	11

174	The performance of acoustic radiation force impulse imaging in predicting liver fibrosis in chronic liver diseases. <i>Kaohsiung Journal of Medical Sciences</i> , 2016 , 32, 362-6	2.4	18
173	PNPLA3 genetic variants determine hepatic steatosis in non-obese chronic hepatitis C patients. <i>Scientific Reports</i> , 2015 , 5, 11901	4.9	8
172	Host and virological characteristics of patients with hepatitis C virus mixed genotype 1 and 2 infection. <i>Kaohsiung Journal of Medical Sciences</i> , 2015 , 31, 271-7	2.4	3
171	Chronic hepatitis C infection is associated with insulin resistance and lipid profiles. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015 , 30, 879-84	4	41
170	Personalized Therapy of Chronic Hepatitis C and B Dually Infected Patients With Pegylated Interferon Plus Ribavirin: A Randomized Study. <i>Medicine (United States)</i> , 2015 , 94, e1837	1.8	11
169	Amiodarone as an autophagy promoter reduces liver injury and enhances liver regeneration and survival in mice after partial hepatectomy. <i>Scientific Reports</i> , 2015 , 5, 15807	4.9	41
168	Peginterferon plus weight-based ribavirin for treatment-naïve hepatitis C virus genotype 2 patients not achieving rapid virologic response: a randomized trial. <i>Scientific Reports</i> , 2015 , 5, 11710	4.9	7
167	Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Naïve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial. <i>Scientific Reports</i> , 2015 , 5, 15255	4.9	7
166	The tertiary prevention of hepatocellular carcinoma in chronic hepatitis C patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015 , 30, 1768-74	4	12
165	Huge gap between clinical efficacy and community effectiveness in the treatment of chronic hepatitis C: a nationwide survey in Taiwan. <i>Medicine (United States)</i> , 2015 , 94, e690	1.8	71
164	Hyperuricemia Inversely Correlates with Disease Severity in Taiwanese Nonalcoholic Steatohepatitis Patients. <i>PLoS ONE</i> , 2015 , 10, e0139796	3.7	12
163	Serological investigation to identify risk factors for post-flood infectious diseases: a longitudinal survey among people displaced by Typhoon Morakot in Taiwan. <i>BMJ Open</i> , 2015 , 5, e007008	3	9
162	Neoadjuvant transcatheter arterial chemoembolization does not provide survival benefit compared to curative therapy alone in single hepatocellular carcinoma. <i>Kaohsiung Journal of Medical Sciences</i> , 2015 , 31, 77-82	2.4	9
161	Clinical performance of a new hepatitis B surface antigen quantitative assay with automatic dilution. <i>Kaohsiung Journal of Medical Sciences</i> , 2015 , 31, 26-33	2.4	1
160	Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naïve patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial. <i>Gut</i> , 2015 , 64, 303-11	19.2	32
159	Association of diabetes and PNPLA3 genetic variants with disease severity of patients with chronic hepatitis C virus infection. <i>Journal of Hepatology</i> , 2015 , 62, 512-8	13.4	28
158	Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients. <i>PLoS ONE</i> , 2015 , 10, e0122259	3.7	14
157	Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication. <i>Journal of Hepatology</i> , 2014 , 61, 67-74	13.4	91

156	Hepatitis C viremia interferes with serum hepatitis B virus surface antigen and DNA levels in hepatitis B uremics. <i>Hepatology International</i> , 2014 , 8, 224-32	8.8	12
155	Peripheral blood mononuclear cells microRNA predicts treatment outcome of hepatitis C virus genotype 1 infection. <i>Antiviral Research</i> , 2014 , 105, 135-42	10.8	13
154	Comparison of the Abbott RealTime HBV assay with the Roche Cobas AmpliPrep/Cobas TaqMan HBV assay for HBV DNA detection and quantification. <i>Journal of Clinical Virology</i> , 2014 , 60, 206-14	14.5	31
153	High hepatitis B virus surface antigen levels and favorable interleukin 28B genotype predict spontaneous hepatitis C virus clearance in uremic patients. <i>Journal of Hepatology</i> , 2014 , 60, 253-9	13.4	45
152	Hepatitis C virus infection among injection drug users with and without human immunodeficiency virus co-infection. <i>PLoS ONE</i> , 2014 , 9, e94791	3.7	36
151	Abbott RealTime HBV assay is more sensitive in detection of low viral load and little impacted by drug resistant mutation in chronic hepatitis B patients under nucleot(s)ide analogues therapy. <i>PLoS ONE</i> , 2014 , 9, e101790	3.7	8
150	Discrepancy between serological and virological analysis of viral hepatitis in hemodialysis patients. <i>International Journal of Medical Sciences</i> , 2014 , 11, 436-41	3.7	13
149	Treatment efficacy of pegylated interferon plus ribavirin therapy in chronic hepatitis C patients with mixed genotype 1/2 infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014 , 29, 1012-8	4	8
148	Cirrhosis as a risk factor for tuberculosis infection--a nationwide longitudinal study in Taiwan. <i>American Journal of Epidemiology</i> , 2014 , 180, 103-10	3.8	26
147	Hepatitis C transmission from viremic donors in hematopoietic stem cell transplant. <i>Transplant Infectious Disease</i> , 2014 , 16, 1003-6	2.7	11
146	Impact of chronic hepatitis B and hepatitis C on adverse hepatic fibrosis in hepatocellular carcinoma related to betel quid chewing. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014 , 15, 637-42	1.7	15
145	Risk interaction of obesity, insulin resistance and hormone-sensitive lipase promoter polymorphisms (LIPE-60 C > G) in the development of fatty liver. <i>BMC Medical Genetics</i> , 2013 , 14, 54	2.1	12
144	Interferon-associated hepatic steatosis is related to discrepancies in biochemical and virological responses of chronic hepatitis C to IFN-based therapy. <i>Hepatology International</i> , 2013 , 7, 162-70	8.8	3
143	The safety and efficacy of peginterferon plus ribavirin in hepatitis C patients concomitant with malignancy other than hepatocellular carcinoma: a multicenter study. <i>Hepatology International</i> , 2013 , 7, 180-7	8.8	2
142	Survival comparison between surgical resection and percutaneous radiofrequency ablation for patients in Barcelona Clinic Liver Cancer early stage hepatocellular carcinoma. <i>Indian Journal of Gastroenterology</i> , 2013 , 32, 253-7	1.9	22
141	Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up. <i>Hepatology</i> , 2013 , 57, 2135-42	11.2	55
140	Profound week 4 interferon responsiveness is mandatory for hepatitis C genotype 1 patients with unfavorable IL-28B genotype. <i>Journal of Clinical Virology</i> , 2013 , 56, 293-8	14.5	19
139	Host factors determining the efficacy of hepatitis C treatment. <i>Journal of Gastroenterology</i> , 2013 , 48, 22-30	6.9	24

138	Clinical utility of host genetic IL-28B variants in hepatitis C virus genotype 1 Asian patients retreated with pegylated interferon plus ribavirin. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013 , 28, 1515-20	4	14
137	Outcome assessment in acute pancreatitis patients. <i>Kaohsiung Journal of Medical Sciences</i> , 2013 , 29, 469-77	2.4	8
136	Association between gallbladder stones and chronic hepatitis C: ultrasonographic survey in a hepatitis C and B hyperendemic township in Taiwan. <i>Kaohsiung Journal of Medical Sciences</i> , 2013 , 29, 430-5	2.4	6
135	Glucose abnormalities in hepatitis C virus infection. <i>Kaohsiung Journal of Medical Sciences</i> , 2013 , 29, 61-82.4	2.4	20
134	Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversion. <i>Hepatology</i> , 2013 , 57, 934-43	11.2	45
133	Consolidation therapy for HBeAg-positive Asian chronic hepatitis B patients receiving lamivudine treatment: a multicentre study. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 2332-8	5.1	16
132	Pegylated interferon- α with or without low-dose ribavirin for treatment-naïve patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. <i>Annals of Internal Medicine</i> , 2013 , 159, 729-38	8	79
131	Virological predictors of response to retreatment in hepatitis C genotype 2 infected patients. <i>PLoS ONE</i> , 2013 , 8, e58882	3.7	12
130	Mitochondrial polymorphism 12361A>G is associated with nonalcoholic fatty liver disease. <i>Translational Research</i> , 2012 , 159, 58-9	11	9
129	The outcomes of glucose abnormalities in pre-diabetic chronic hepatitis C patients receiving peginterferon plus ribavirin therapy. <i>Liver International</i> , 2012 , 32, 962-9	7.9	18
128	Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin. <i>Journal of Hepatology</i> , 2012 , 56, 34-40	13.4	75
127	Tarry stool in a man with acute pancreatitis. <i>Gastroenterology</i> , 2012 , 143, e5-6	13.3	
126	Antinuclear antibody titer and treatment response to peginterferon plus ribavirin for chronic hepatitis C patients. <i>Kaohsiung Journal of Medical Sciences</i> , 2012 , 28, 86-93	2.4	9
125	Thyroid autoantibodies and dysfunction do not impact the treatment efficacy of peginterferon and ribavirin combination therapy in chronic hepatitis C. <i>Hepatology International</i> , 2012 , 6, 613-9	8.8	4
124	APASL consensus statements and management algorithms for hepatitis C virus infection. <i>Hepatology International</i> , 2012 , 6, 409-35	8.8	139
123	Host interleukin-28B genetic variants versus viral kinetics in determining responses to standard-of-care for Asians with hepatitis C genotype 1. <i>Antiviral Research</i> , 2012 , 93, 239-244	10.8	42
122	Revisiting the stopping rule for hepatitis C genotype 1 patients treated with peginterferon plus ribavirin. <i>PLoS ONE</i> , 2012 , 7, e52048	3.7	22
121	Performance characteristics of a combined hepatitis C virus core antigen and anti-hepatitis C virus antibody test in different patient groups. <i>Kaohsiung Journal of Medical Sciences</i> , 2011 , 27, 258-63	2.4	15

120	The efficacy and safety of pegylated interferon plus ribavirin combination therapy in chronic hepatitis c patients with hepatocellular carcinoma post curative therapies - a multicenter prospective trial. <i>Journal of Hepatology</i> , 2011 , 54, 219-26	13.4	21
119	Hepatic Akt expression correlates with advanced fibrosis in patients with chronic hepatitis C infection. <i>Hepatology Research</i> , 2011 , 41, 430-6	5.1	9
118	Serum visfatin is correlated with disease severity and metabolic syndrome in chronic hepatitis C infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011 , 26, 530-5	4	10
117	The PNPLA3 I148M polymorphism is associated with insulin resistance and nonalcoholic fatty liver disease in a normoglycaemic population. <i>Liver International</i> , 2011 , 31, 1326-31	7.9	53
116	Pegylated interferon plus ribavirin therapy improves pancreatic β cell function in chronic hepatitis C patients. <i>Liver International</i> , 2011 , 31, 1155-62	7.9	12
115	Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients. <i>Hepatology</i> , 2011 , 53, 7-13	11.2	155
114	Linkage of the hepatitis C virus genotype and interleukin-28B genetic polymorphisms in Asian patients. <i>Hepatology</i> , 2011 , 53, 367-8; author reply 368	11.2	13
113	Insurance status and treatment candidacy of patients with hepatitis C: Taiwanese patients are luckier. <i>Hepatology</i> , 2011 , 53, 1399; author reply 1400	11.2	4
112	Association between virological response and decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in HCV genotype 1: another story. <i>Hepatology</i> , 2011 , 53, 1774-5; author reply 1775-6	11.2	1
111	Outcome of patients suffering from a spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure and treated with antivirals. <i>Hepatology</i> , 2011 , 54, 1108-9	11.2	2
110	Long-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses. <i>PLoS ONE</i> , 2011 , 6, e20752	3.7	17
109	Early identification of achieving a sustained virological response in chronic hepatitis C patients without a rapid virological response. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010 , 25, 758-65	4	22
108	Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C. <i>Journal of Infectious Diseases</i> , 2010 , 201, 751-9	7	315
107	HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. <i>Journal of Infectious Diseases</i> , 2010 , 202, 86-92	7	42
106	Insulin resistance, viral load and response to peginterferon and ribavirin in patients with chronic hepatitis C virus infection. <i>Gut</i> , 2010 , 59, 418	19.2	2
105	Hepatitis C virus viremia and low platelet count: a study in a hepatitis B & C endemic area in Taiwan. <i>Journal of Hepatology</i> , 2010 , 52, 160-6	13.4	38
104	Intestinal parasitic infection detected by stool examination in foreign laborers in Kaohsiung. <i>Kaohsiung Journal of Medical Sciences</i> , 2010 , 26, 136-43	2.4	11
103	Viral hepatitis infections in southern Taiwan: a multicenter community-based study. <i>Kaohsiung Journal of Medical Sciences</i> , 2010 , 26, 461-9	2.4	83

102	Hepatitis B virus genotyping by enzyme-linked immunosorbent assay in Taiwan. <i>Hepatology International</i> , 2010 , 4, 601-7	8.8	10
101	Serum hs-CRP was correlated with treatment response to pegylated interferon and ribavirin combination therapy in chronic hepatitis C patients. <i>Hepatology International</i> , 2010 , 4, 621-7	8.8	19
100	Comparison of adverse effects related to pegylated interferon-based therapy for patients with chronic hepatitis B and chronic hepatitis C in Taiwan. <i>Hepatology International</i> , 2010 , 4, 732-40	8.8	14
99	Human leukocyte antigen alleles and the response to pegylated interferon/ribavirin therapy in chronic hepatitis C patients. <i>Antiviral Research</i> , 2010 , 85, 396-402	10.8	15
98	Hepatitis C virus genotype 2/3 patients who can receive an abbreviated course of peginterferon/ribavirin: the important role of initial ribavirin doses. <i>Hepatology</i> , 2010 , 51, 1861-2; author reply 1862-4	11.2	0
97	Unveiling glucose abnormalities in patients with chronic hepatitis C infection. <i>American Journal of Gastroenterology</i> , 2009 , 104, 1051; author reply 1052	0.7	
96	The substantial role of initial ribavirin dose on the response to peginterferon alpha/ribavirin therapy in patients with genotype 1b chronic hepatitis C. <i>American Journal of Gastroenterology</i> , 2009 , 104, 2358-9	0.7	
95	Hepatitis B e antigen-negative patients with persistently normal alanine aminotransferase levels and hepatitis B virus DNA > 2000 IU/mL. <i>Hepatology</i> , 2009 , 49, 704-5; author reply 705-6	11.2	5
94	Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in patients with chronic hepatitis C, using viral and host factors: some concerns. <i>Hepatology</i> , 2009 , 49, 2125; author reply 2125-6	11.2	1
93	A crossing in therapy for hepatitis C virus genotype 2 or 3: increasing ribavirin dose with shortened duration or reducing ribavirin dose with standard duration. <i>Hepatology</i> , 2009 , 49, 1395-6; author reply 1396	11.2	3
92	Bacterial infection and neutropenia during peginterferon plus ribavirin combination therapy in patients with chronic hepatitis C with and without baseline neutropenia in clinical practice. <i>Alimentary Pharmacology and Therapeutics</i> , 2009 , 29, 1000-10	6.1	18
91	Abnormal liver function test results are related to metabolic syndrome and BMI in Taiwanese adults without chronic hepatitis B or C. <i>International Journal of Obesity</i> , 2009 , 33, 1309-17	5.5	22
90	Treatment of chronic hepatitis C in Asia: when East meets West. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009 , 24, 336-45	4	203
89	HBV infection in indigenous children, 20 years after immunization in Taiwan: a community-based study. <i>Preventive Medicine</i> , 2009 , 48, 397-400	4.3	10
88	What can be revealed by extending the sensitivity of HBsAg detection to below the present limit? Beyond the applause for higher sensitivity. <i>Journal of Hepatology</i> , 2009 , 50, 212; author reply 213	13.4	
87	Serum retinol-binding protein 4 is inversely correlated with disease severity of chronic hepatitis C. <i>Journal of Hepatology</i> , 2009 , 50, 471-8	13.4	18
86	Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients. <i>Journal of Hepatology</i> , 2009 , 50, 712-8	13.4	124
85	Performance characteristics of two real-time PCR assays for quantification of hepatitis B virus DNA. <i>Scandinavian Journal of Infectious Diseases</i> , 2009 , 41, 614-8		12

84	Hepatitis C virus infection and metabolic syndrome---a community-based study in an endemic area of Taiwan. <i>Kaohsiung Journal of Medical Sciences</i> , 2009 , 25, 299-305	2.4	27
83	Comparison of clinical application of the Abbott HBV PCR kit and the VERSANT HBV DNA 3.0 test to measure serum hepatitis B virus DNA in Taiwanese patients. <i>Kaohsiung Journal of Medical Sciences</i> , 2009 , 25, 413-22	2.4	9
82	Hepatocellular carcinoma associated with liver abscess. <i>Kaohsiung Journal of Medical Sciences</i> , 2009 , 25, 537-43	2.4	11
81	Association between transforming growth factor-beta 1 polymorphism and virologic characteristics of chronic hepatitis C. <i>Translational Research</i> , 2008 , 152, 151-6	11	6
80	Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels: a community-based study. <i>Journal of Hepatology</i> , 2008 , 49, 9-16	13.4	114
79	Performance characteristics of a real-time RT-PCR assay for quantification of hepatitis C virus RNA in patients with genotype 1 and 2 infections. <i>Clinical Chemistry and Laboratory Medicine</i> , 2008 , 46, 475-80	5.9	4
78	Abnormal liver function test predicts type 2 diabetes: a community-based prospective study: response to Cho et al. <i>Diabetes Care</i> , 2008 , 31, e53	14.6	5
77	Revisit of oral glucose tolerance test: a must for diagnosis of type 2 diabetes in patients with chronic hepatitis C. <i>American Journal of Gastroenterology</i> , 2008 , 103, 487-8; author reply 488	0.7	1
76	Reappraisal of the characteristics of glucose abnormalities in patients with chronic hepatitis C infection. <i>American Journal of Gastroenterology</i> , 2008 , 103, 1933-40	0.7	42
75	High serum uric acid as a novel risk factor for type 2 diabetes: response to Dehghan et al. <i>Diabetes Care</i> , 2008 , 31, e67	14.6	4
74	Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: Some issues. <i>Hepatology</i> , 2008 , 47, 1792-3; author reply 1793-4	11.2	1
73	Possible determinants of rapid virological response suggesting shorter courses of combination therapy for hepatitis C virus genotype 2. <i>Hepatology</i> , 2008 , 48, 342	11.2	1
72	Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. <i>Hepatology</i> , 2008 , 47, 1884-93	11.2	263
71	Rapid virological response in hepatitis C virus genotype 1 and early ribavirin exposure. <i>Hepatology</i> , 2008 , 48, 692-3; author reply 693-4	11.2	
70	Rapid virological response to peginterferon and ribavirin for hepatitis C genotype 1: the role of weight-based ribavirin exposure. <i>Hepatology</i> , 2008 , 48, 1019-20; author reply 1020-1	11.2	11
69	Changing prevalence of hepatitis C virus infection among teenagers in an endemic area in Taiwan. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2008 , 102, 929-34	2	12
68	Hepatitis C virus infection among children in aboriginal areas in Taiwan. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2008 , 102, 935-8	2	9
67	Antinuclear antibody is associated with a more advanced fibrosis and lower RNA levels of hepatitis C virus in patients with chronic hepatitis C. <i>Journal of Clinical Pathology</i> , 2008 , 61, 333-7	3.9	34

66	Comparison of liver histopathology between chronic hepatitis C patients and chronic hepatitis B and C-coinfected patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007 , 22, 515-7	4	43
65	Significant correlations between severe fatty liver and risk factors for metabolic syndrome. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007 , 22, 2118-23	4	102
64	Sustained virological response to interferon reduces cirrhosis in chronic hepatitis C: a 1,386-patient study from Taiwan. <i>Alimentary Pharmacology and Therapeutics</i> , 2007 , 25, 1029-37	6.1	58
63	Early response to lamivudine therapy in clinically non-cirrhotic chronic hepatitis B patients with decompensation. <i>Liver International</i> , 2007 , 27, 1364-70	7.9	8
62	Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B. <i>Antiviral Research</i> , 2007 , 75, 146-51	10.8	19
61	Prevention of donor to recipient transmission of HCV in stem cell transplantation: some issues. <i>American Journal of Gastroenterology</i> , 2007 , 102, 2350-1; author reply 2351-2	0.7	
60	Hepatitis C viremia increases the association with type 2 diabetes mellitus in a hepatitis B and C endemic area: an epidemiological link with virological implication. <i>American Journal of Gastroenterology</i> , 2007 , 102, 1237-43	0.7	95
59	The incidence and risks of liver biopsy in non-cirrhotic patients: An evaluation of 3806 biopsies. <i>Gut</i> , 2007 , 56, 736-7	19.2	49
58	Long-term effects of interferon-based therapy for chronic hepatitis C. <i>Oncology</i> , 2007 , 72 Suppl 1, 16-23	3.6	29
57	The role of gender on clearance of hepatitis C virus: a different story in an area endemic for hepatitis B and C. <i>Gut</i> , 2007 , 56, 737-8	19.2	7
56	A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. <i>Gut</i> , 2007 , 56, 553-9	19.2	222
55	Qualitative application of COBAS AMPLICOR HCV test version 2.0 assays in patients with chronic hepatitis C virus infection and comparison of clinical performance with version 1.0. <i>Kaohsiung Journal of Medical Sciences</i> , 2007 , 23, 332-8	2.4	3
54	Tumor necrosis factor-alpha 308.2 polymorphism is associated with advanced hepatic fibrosis and higher risk for hepatocellular carcinoma. <i>Neoplasia</i> , 2007 , 9, 987-92	6.4	71
53	Links between triglyceride levels, hepatitis C virus infection and diabetes. <i>Gut</i> , 2007 , 56, 1167-8	19.2	5
52	Hepatic steatosis and fibrosis in chronic hepatitis C in Taiwan. <i>Japanese Journal of Infectious Diseases</i> , 2007 , 60, 377-81	2.7	20
51	A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy. <i>Hepatology</i> , 2006 , 44, 1086-97	11.2	97
50	Tumor necrosis factor- alpha promoter polymorphism at position -308 predicts response to combination therapy in hepatitis C virus infection. <i>Journal of Infectious Diseases</i> , 2006 , 193, 98-101	7	59
49	Treatment of chronic hepatitis C in southern Taiwan. <i>Intervirology</i> , 2006 , 49, 99-106	2.5	62

48	SEN and hepatitis virus infections in nontransfused children and pediatric thalassemia patients with multiple transfusions in Taiwan. <i>Digestion</i> , 2006 , 74, 208-14	3.6	4
47	Etiology, severity and recurrence of acute pancreatitis in southern taiwan. <i>Journal of the Formosan Medical Association</i> , 2006 , 105, 550-5	3.2	25
46	Early mortality in Taiwanese lamivudine-treated patients with chronic hepatitis B-related decompensation: evaluation of the model for end-stage liver disease and index scoring systems as prognostic predictors. <i>Clinical Therapeutics</i> , 2006 , 28, 2081-92	3.5	22
45	Diagnosis of icteric-type hepatocellular carcinoma by fine needle aspiration: a case report. <i>Acta Cytologica</i> , 2006 , 50, 531-3	3	3
44	Discordant influence of amphotericin B on epirubicin cytotoxicity in primary hepatic malignant cells collected by a new primary culture technique. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2006 , 21, 398-405	4	6
43	A randomized trial of 24- vs. 48-week courses of PEG interferon alpha-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan. <i>Liver International</i> , 2006 , 26, 73-81	7.9	41
42	A 24-week course of high-dose interferon-alpha plus ribavirin for Taiwanese chronic hepatitis C patients with persistently normal or near-normal alanine aminotransferase levels. <i>Liver International</i> , 2006 , 26, 1187-95	7.9	7
41	Hyperleptinaemia and hypoadiponectinaemia are associated with gallstone disease. <i>European Journal of Clinical Investigation</i> , 2006 , 36, 176-80	4.6	19
40	Viral hepatitis and proteinuria in an area endemic for hepatitis B and C infections: another chain of link?. <i>Journal of Internal Medicine</i> , 2006 , 260, 255-62	10.8	73
39	The role of thyroid autoantibodies in the development of thyroid dysfunction in Taiwanese chronic hepatitis C patients with interferon-alpha and ribavirin combination therapy. <i>Journal of Viral Hepatitis</i> , 2006 , 13, 396-401	3.4	25
38	Associations of tumour necrosis factor alpha promoter polymorphisms at position -308 and -238 with clinical characteristics of chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2006 , 13, 770-4	3.4	22
37	Selenium, iron, copper, and zinc levels and copper-to-zinc ratios in serum of patients at different stages of viral hepatic diseases. <i>Biological Trace Element Research</i> , 2006 , 109, 15-24	4.5	63
36	Primary hepatocellular carcinoma detected long after tumor markers and lymph node metastases--beyond our vision?. <i>Digestive Diseases and Sciences</i> , 2006 , 51, 610-5	4	1
35	Outcome of chronic hepatitis C patients who required early termination of pegylated interferon-alpha plus ribavirin combination therapy. <i>Antiviral Therapy</i> , 2006 , 11, 1015-9	1.6	6
34	Outcome of Chronic Hepatitis C Patients who Required Early Termination of Pegylated Interferon- α plus Ribavirin Combination Therapy. <i>Antiviral Therapy</i> , 2006 , 11, 1015-1020	1.6	23
33	Serum insulin-like growth factor-II as a serologic marker of small hepatocellular carcinoma. <i>Scandinavian Journal of Gastroenterology</i> , 2005 , 40, 68-75	2.4	40
32	SEN virus infection among patients on maintenance hemodialysis in southern Taiwan. <i>Journal of Infection</i> , 2005 , 51, 110-5	18.9	7
31	Safety of fine-needle aspiration in patients with small hepatocellular carcinoma. <i>Hepatology Research</i> , 2005 , 31, 31-35	5.1	9

30	Polymorphisms in the interferon-gamma gene at position +874 in patients with chronic hepatitis C treated with high-dose interferon-alpha and ribavirin. <i>Antiviral Research</i> , 2005 , 67, 93-7	10.8	19
29	Co-infection of SENV-D among chronic hepatitis C patients treated with combination therapy with high-dose interferon-alfa and ribavirin. <i>World Journal of Gastroenterology</i> , 2005 , 11, 4241-5	5.6	6
28	Randomized trial of three different regimens for 24 weeks for re-treatment of chronic hepatitis C patients who failed to respond to interferon-alpha monotherapy in Taiwan. <i>Liver International</i> , 2004 , 24, 595-602	7.9	14
27	CT evaluation of gastrointestinal tract perforation. <i>Clinical Imaging</i> , 2004 , 28, 329-33	2.7	54
26	A prospective study on treatment of chronic hepatitis C with tailored and extended interferon-alpha regimens according to pretreatment virological factors. <i>Antiviral Research</i> , 2004 , 63, 25-32	10.8	17
25	Prevalence and clinical significance of SEN virus infection among volunteer blood donors in southern Taiwan. <i>Digestive Diseases and Sciences</i> , 2004 , 49, 1181-5	4	5
24	Imaging of transmural migration of a retained surgical sponge: a case report. <i>Kaohsiung Journal of Medical Sciences</i> , 2004 , 20, 567-71	2.4	12
23	Serum insulin-like growth factor-II and alpha-fetoprotein as tumor markers of hepatocellular carcinoma. <i>Tumor Biology</i> , 2003 , 24, 291-8	2.9	30
22	Tumor necrosis factor alpha promoter polymorphisms at position -308 in Taiwanese chronic hepatitis C patients treated with interferon-alpha. <i>Antiviral Research</i> , 2003 , 59, 35-40	10.8	19
21	The response of hepatitis C virus and TT virus to high dose and long duration interferon-alpha therapy in naïve chronic hepatitis C patients. <i>Antiviral Research</i> , 2002 , 53, 9-18	10.8	8
20	Incidence and clinical outcome of icteric type hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2002 , 17, 190-5	4	54
19	Clinical characteristics and distribution of genotypes of TT virus infection in a hepatitis C virus-hyperendemic township of a hepatitis B virus-endemic country (Taiwan). <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2002 , 17, 1192-7	4	2
18	The prevalence of TT virus and GB virus C/hepatitis G virus infection in individuals with raised liver enzymes but without HBV or HCV infection in Taiwan. <i>Epidemiology and Infection</i> , 2002 , 129, 307-13	4.3	4
17	Influence of hepatitis C virus on the profiles of patients with chronic hepatitis B virus infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2001 , 16, 636-40	4	45
16	Changing prevalence of hepatitis C virus genotypes: Molecular epidemiology and clinical implications in the hepatitis C virus hyperendemic areas and a tertiary referral center in Taiwan. <i>Journal of Medical Virology</i> , 2001 , 65, 58-65	19.7	73
15	The serological and molecular epidemiology of GB virus C/hepatitis G virus infection in a hepatitis C and B endemic area. <i>Journal of Infection</i> , 2001 , 42, 61-6	18.9	12
14	GB virus C/hepatitis G virus infection in chronic hepatitis C patients with and without interferon-alpha therapy. <i>Antiviral Research</i> , 2001 , 52, 241-9	10.8	15
13	The molecular epidemiology and clinical significance of TT virus (TTV) infection in healthy blood donors from southern Taiwan. <i>Transfusion and Apheresis Science</i> , 2001 , 24, 9-15	2.4	8

12	Hepatitis C virus infection among teenagers in an endemic township in Taiwan: epidemiological and clinical follow-up studies. <i>Epidemiology and Infection</i> , 2001 , 127, 485-92	4.3	28
11	Role of serum C-reactive protein as a marker of hepatocellular carcinoma in patients with cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000 , 15, 417-21	4	20
10	Serotyping and genotyping of hepatitis C virus in Taiwanese patients with type C chronic liver disease and uraemic patients on maintenance haemodialysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000 , 15, 792-7	4	6
9	Status and natural course of GB virus C/hepatitis G virus infection among high-risk groups and volunteer blood donors in Taiwan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000 , 15, 1404-10	4.10	12
8	Clinical evaluation of the automated COBAS AMPLICOR HCV MONITOR test version 2.0 for quantifying serum hepatitis C virus RNA and comparison to the quantiplex HCV version 2.0 test. <i>Journal of Clinical Microbiology</i> , 2000 , 38, 2933-9	9.7	44
7	Incidence and associated factors of neutralizing anti-interferon antibodies among chronic hepatitis C patients treated with interferon in Taiwan. <i>Scandinavian Journal of Gastroenterology</i> , 2000 , 35, 1288-93	3.4	14
6	Percutaneous ethanol injection of the supplying artery to hepatocellular carcinoma that is not amenable to conventional treatment. <i>British Journal of Radiology</i> , 2000 , 73, 833-9	3.4	3
5	Virologic factors related to interferon-alpha-induced thyroid dysfunction in patients with chronic hepatitis C. <i>European Journal of Endocrinology</i> , 2000 , 142, 431-7	6.5	55
4	A hyperendemic community of hepatitis B virus and hepatitis C virus infection in Taiwan. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 1999 , 93, 253-4	2	35
3	Prevalence and manifestations of hepatitis C seropositivity in children in an endemic area. <i>Pediatric Infectious Disease Journal</i> , 1998 , 17, 142-5	3.4	30
2	Different viral aetiology of hepatocellular carcinoma between two hepatitis B and C endemic townships in Taiwan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1997 , 12, 547-50	4	42
1	Hepatic focal nodular hyperplasia: findings on color Doppler ultrasound. <i>Abdominal Imaging</i> , 1997 , 22, 178-81		49